Hikma licenses middle east rights to Astellas's Advagraf
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals has obtained exclusive rights to distribute and promote the immunosuppressant Advagraf, the prolonged-release, once-daily formulation of Astellas's Prograf (tacrolimus), in 17 countries in the middle east and north Africa (MENA).